JPWO2021076564A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021076564A5 JPWO2021076564A5 JP2022522657A JP2022522657A JPWO2021076564A5 JP WO2021076564 A5 JPWO2021076564 A5 JP WO2021076564A5 JP 2022522657 A JP2022522657 A JP 2022522657A JP 2022522657 A JP2022522657 A JP 2022522657A JP WO2021076564 A5 JPWO2021076564 A5 JP WO2021076564A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- cdr2
- cdr3
- cdr1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 86
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 53
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 53
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 53
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 53
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 53
- 102000004169 proteins and genes Human genes 0.000 claims 37
- 108090000623 proteins and genes Proteins 0.000 claims 37
- 239000000427 antigen Substances 0.000 claims 34
- 102000036639 antigens Human genes 0.000 claims 34
- 108091007433 antigens Proteins 0.000 claims 34
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims 23
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims 19
- 102000004196 processed proteins & peptides Human genes 0.000 claims 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims 15
- 229920001184 polypeptide Polymers 0.000 claims 14
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 9
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 6
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 6
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 238000006467 substitution reaction Methods 0.000 claims 5
- 102000049850 human FLT3 Human genes 0.000 claims 4
- 230000035772 mutation Effects 0.000 claims 4
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 4
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 206010066476 Haematological malignancy Diseases 0.000 claims 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 238000010494 dissociation reaction Methods 0.000 claims 2
- 230000005593 dissociations Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 1
- IPWKGIFRRBGCJO-IMJSIDKUSA-N Ala-Ser Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](CO)C([O-])=O IPWKGIFRRBGCJO-IMJSIDKUSA-N 0.000 claims 1
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 claims 1
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 claims 1
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 claims 1
- 241000282567 Macaca fascicularis Species 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 claims 1
- YKRQRPFODDJQTC-CSMHCCOUSA-N Thr-Lys Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN YKRQRPFODDJQTC-CSMHCCOUSA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000001608 potassium adipate Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962915123P | 2019-10-15 | 2019-10-15 | |
| US62/915,123 | 2019-10-15 | ||
| PCT/US2020/055497 WO2021076564A1 (en) | 2019-10-15 | 2020-10-14 | Proteins binding nkg2d, cd16 and flt3 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022551969A JP2022551969A (ja) | 2022-12-14 |
| JPWO2021076564A5 true JPWO2021076564A5 (enrdf_load_stackoverflow) | 2023-10-19 |
Family
ID=75538862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022522657A Pending JP2022551969A (ja) | 2019-10-15 | 2020-10-14 | Ｎｋｇ２ｄ、ｃｄ１６およびｆｌｔ３に結合するタンパク質 |
Country Status (16)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2986967T3 (es) | 2018-02-08 | 2024-11-13 | Dragonfly Therapeutics Inc | Combinaciones de dominios variables de anticuerpos dirigidas al receptor NKG2D |
| SG11202007579TA (en) | 2018-02-08 | 2020-09-29 | Dragonfly Therapeutics Inc | Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells |
| CA3108646A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and a tumor-associated antigen |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| WO2020033630A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| CN117222663A (zh) | 2021-03-03 | 2023-12-12 | 蜻蜓疗法股份有限公司 | 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法 |
| EP4334350A1 (en) | 2021-05-05 | 2024-03-13 | Immatics Biotechnologies GmbH | Bma031 antigen binding polypeptides |
| US20240391971A1 (en) * | 2021-08-24 | 2024-11-28 | Sunshine Lake Pharma Co., Ltd. | Gdf15 fusion proteins and uses thereof |
| WO2023056252A1 (en) * | 2021-09-29 | 2023-04-06 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and baff-r |
| US20230203202A1 (en) * | 2021-12-08 | 2023-06-29 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| US20240166705A1 (en) | 2022-11-07 | 2024-05-23 | Xencor, Inc. | Il18-fc fusion proteins |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025179294A2 (en) | 2024-02-22 | 2025-08-28 | Capstan Therapeutics, Inc. | Immune engineering amplification |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR071891A1 (es) * | 2008-05-30 | 2010-07-21 | Imclone Llc | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) |
| ES2628075T3 (es) * | 2011-12-19 | 2017-08-01 | Synimmune Gmbh | Molécula de anticuerpo biespecífica |
| NL2014108B1 (en) * | 2015-01-09 | 2016-09-30 | Aduro Biotech Holdings Europe B V | Altered april binding antibodies. |
| HK1255234A1 (zh) * | 2015-07-16 | 2019-08-09 | 塞勒兰特治疗公司 | 经半胱氨酸取代的免疫球蛋白 |
| US20200165344A1 (en) * | 2017-07-31 | 2020-05-28 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and flt3 |
| US20200231679A1 (en) * | 2017-08-23 | 2020-07-23 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and a tumor-associated antigen |
| US20200277384A1 (en) * | 2017-09-14 | 2020-09-03 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16, and c-type lectin-like molecule-1 (cll-1) |
| ES2986967T3 (es) * | 2018-02-08 | 2024-11-13 | Dragonfly Therapeutics Inc | Combinaciones de dominios variables de anticuerpos dirigidas al receptor NKG2D |
| SG11202007579TA (en) * | 2018-02-08 | 2020-09-29 | Dragonfly Therapeutics Inc | Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells |
| JP7539840B2 (ja) * | 2018-02-20 | 2024-08-26 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｃｄ３３を標的とする抗体可変ドメイン及びその使用 |
| KR102832460B1 (ko) * | 2018-02-20 | 2025-07-11 | 드래곤플라이 쎄라퓨틱스, 인크. | Cd33, nkg2d, 및 cd16에 결합하는 다중-특이적 결합 단백질, 및 이의 사용 방법 |
| EP3773676A4 (en) * | 2018-04-03 | 2022-05-18 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and an antigen associated with tumors, mdscs and/or tams |
-
2020
- 2020-10-14 CN CN202080072319.9A patent/CN115298217A/zh active Pending
- 2020-10-14 KR KR1020227016160A patent/KR20220083770A/ko active Pending
- 2020-10-14 JP JP2022522657A patent/JP2022551969A/ja active Pending
- 2020-10-14 TW TW109135528A patent/TW202128759A/zh unknown
- 2020-10-14 MX MX2022004430A patent/MX2022004430A/es unknown
- 2020-10-14 CA CA3153858A patent/CA3153858A1/en active Pending
- 2020-10-14 WO PCT/US2020/055497 patent/WO2021076564A1/en active Application Filing
- 2020-10-14 PE PE2022000621A patent/PE20221316A1/es unknown
- 2020-10-14 AU AU2020368163A patent/AU2020368163A1/en active Pending
- 2020-10-14 EP EP20876627.9A patent/EP4045538A4/en active Pending
- 2020-10-14 AR ARP200102840A patent/AR120223A1/es unknown
- 2020-10-14 BR BR112022007128A patent/BR112022007128A2/pt unknown
- 2020-10-14 US US17/769,160 patent/US20240117054A1/en active Pending
-
2022
- 2022-04-12 CL CL2022000928A patent/CL2022000928A1/es unknown
- 2022-04-13 IL IL292261A patent/IL292261A/en unknown
- 2022-04-13 CO CONC2022/0004757A patent/CO2022004757A2/es unknown
-
2024
- 2024-12-17 CL CL2024003895A patent/CL2024003895A1/es unknown